The Role of BTKi + Obinutuzumab for 1L Treatment of CLL

CancerNetwork co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts to look out for surrounding the multidisciplinary approach at the upcoming ASH Annual Meeting in San Diego, with some additional tidbits to round out the main event.

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

The updated labeling also includes new information on the recommended dosage of fludarabine phosphate when given with cyclophosphamide and rituximab.

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

The FDA has approved revumenib (Revuforj) for the treatment of patients with relapsed/refractory acute leukemia with a KMT2A translocation in adult and pediatric patients 1 year and older.

Developers are expected to file a supplemental NDA for revumenib in NPM1-mutated AML in the first half of 2025.